A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

NCT ID: NCT03026803

Last Updated: 2017-04-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2014-10-31

Brief Summary

This phase II trial is studying how well giving oxaliplatin and capecitabine together works in treating patients with liver cancer.

Detailed Description

Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving these drugs together may kill more tumor cells.

Conditions

Liver Cancer; Hepatocellular Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Oxaliplatin and Capecitabine

21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14

Group Type: EXPERIMENTAL

Oxaliplatin

Intervention Type: DRUG

Given IV

Capecitabine

Intervention Type: DRUG

Given PO

Interventions

Oxaliplatin

Given IV

Intervention Type: DRUG

Capecitabine

Given PO

Intervention Type: DRUG

Other Intervention Names

Eloxatin; Xeloda

Eligibility Criteria

Inclusion Criteria

• Patients must have histologically confirmed hepatocellular carcinoma which is recurrent, metastatic or unresectable.
• Patients may have up to two prior chemotherapy regimes. In addition, they may have had previous radiation, chemoembolization, and/or alcohol injections.
• Patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, and which has clearly progressed during the observation interval prior to participation in this study. Pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s).
• Karnofsky performance status > 70%.
• Patients should have an expected survival of at least 2 months.
• Leukocytes >3,000/µl
• Absolute neutrophil count >1,500/µl
• Platelets >50,000/µl
• Total bilirubin < 3.0 g/dl
• AST (aspartate aminotransferase) (serum glutamic oxaloacetic transaminase(SGOT)/ALT (alanine aminotransferase) (serum glutamic pyruvic transaminase)(SGPT) < 5 times institutional upper limit of normal
• Creatinine < 2.0 OR measured or calculated creatinine clearance >60 mL/min for patients with creatinine levels above institutional normal
• Brain metastasis is not an exclusion, however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or stereotactic RT.
• Patients with no evidence of clinically significant neuropathy.
• All prior therapy must have been completed at least 4 weeks prior to the patient's entry on this trial.
• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Breastfeeding should be discontinued if the mother is treated with oxaliplatin.
• Subjects with chronic hepatitis B or C may be undergoing treatment with α interferon and/or ribavirin, as long as they meet the other criteria for entry on to this study.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Patients have prior oxaliplatin or xeloda treatment or undergoing therapy with other investigational agents.
• History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy.
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia.
• HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the study because of possible pharmacokinetic interactions.
• Patients with a diagnosis of pulmonary fibrosis or a pulmonary interstitial process.
• Patients unable to swallow capecitabine will be excluded from this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: collaborator

City of Hope Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yun Yen, MD

Role: PRINCIPAL_INVESTIGATOR

City of Hope Medical Center

Locations

City of Hope Medical Center

Duarte, California, United States

Countries

United States

Other Identifiers

05195

Identifier Type: -

Identifier Source: org_study_id